Gout A Roadmap to Approaches for Improving Global Outcomes - eScholarship

Gout: A roadmap to approaches for improving global outcomes Nicola Dalbeth 1 *, Hyon K. Choi 2 *, Robert Terkeltaub 3 *contributed equally to this manuscript Nicola Dalbeth MB ChB, MD, Bone & Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand. n.dalbeth@auckland.ac.nz Hyon K. Choi, MD, PhD, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA hchoi@mgh.harvard.edu Robert Terkeltaub, MD, VA San Diego Healthcare System, San Diego, CA, Dept. of Medicine, University of California San Diego, San Diego, CA rterkeltaub@ucsd.edu Supported by the Health Research Council of New Zealand (9101-3708025)(ND), NIH (R01AR065944)(HKC), and VA Research Service (RT). Dr. Dalbeth has received grant support from AstraZeneca and has participated on speaker bureaus for Menarini, ARDEA/Astra-Zeneca, Takeda, and as a consultant for Astra-Zeneca, Fonterra, Takeda, Pfizer, CymaBay, and Crealta. Dr. Choi has served as consultant for Takeda and ARDEA/Astra-Zeneca. Dr. Terkeltaub has served as a consultant for ARDEA/Astra-Zeneca, SOBI, Revive, Selecta, Aequus, ProteoThera, Horizon, Relburn, and CymaBay. Correspondence to: Robert Terkeltaub MD, VA San Diego Healthcare System, 111K, 3350 La Jolla Village Drive, San Diego, CA 92161. Telephone: 858 642 3519. Fax: 858 552 7425, email: rterkeltaub@ucsd.edu Running Head: Roadmap to improved gout outcomes Keywords: Hyperuricemia, ABCG2, URAT1, NLRP3 inflammasome, Precision Medicine